US science and technology group Danaher has entered into a definitive agreement to acquire Abcam, a supplier of life science research tools. Danaher will buy all of the outstanding shares of Abcam for $24.00 per share. The transaction, which is worth about $5.7 billion, is expected to close in mid-2024.
Abcam, a biotech supplier, has garnered interest from major US life sciences companies Danaher and Agilent as it explores its potential sale. The company has also approached Germany’s Merck and attracted attention from large buyout firms, say sources of Bloomberg.
US science and technology group Danaher has agreed to pay $9.6 billion to buy Aldevron, a compatriot contract developer and manufacturer of biologics for the pharmaceutical and biotechnology sectors.
German pharma and laboratory equipment supplier Sartorius completed its $825 million purchase of certain life science businesses of Danaher Corps at the end of April.
